The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma.
Though 100 kinase inhibitors are approved for clinical use, most kinases in the genome remain poorly characterized. Moreover, though kinase inhibitors have revolutionized the care of selected cancers, most others respond transiently or not at all to these drugs, typically directed against signal-transduction pathways....